A clinical study of 55 patients undergoing transfemoral TAVR/TAVI found a mean time to hemostasis of 0.5 ± 2.0 minutes with Ladera Medical’s investigational closure system. At 30 days, 98.1% of patients with available data were free of major access-site complications, according to results presented at London Valves 2026.
Jan van der Heyden, an interventional cardiologist at St. Jan Hospital in Bruges, Belgium, presented the full FASTEN results in a Late-Breaking Clinical Trials session on Nov. 22. The prospective, multicenter, single-arm study enrolled patients at six sites in Australia, Belgium and the Netherlands. An independent clinical events committee adjudicated the primary safety endpoint: freedom from major complications at the target-limb access site through 30 days.
Among the reported results, 52 of 53 patients (98.1%) were free of major access-site complications at 30 days, and the same number were free of minor complications. Technical success was 94.5% (52/55); treatment success, defined as technical success with freedom from major complications, was 94.3% (50/53). Median time to hemostasis was zero minutes. Mean time to ambulation was 14.3 ± 14.5 hours.
Van der Heyden said the suture-based system was intuitive for operators and could be used before or after a procedure. He added that guidewire access is maintained during closure, allowing an alternative course if a problem arises. Associate Professor Robert Gooley of Monash Health in Melbourne, a leading FASTEN enroller, said large-bore access-site complications remain a risk as TAVI becomes routine. He described a need for a single device that can provide suture closure at this size; he presented preliminary study results at EuroPCR 2026.
The Ladera system uses two parallel sutures and is designed for femoral arteriotomies from 10F to 24F, with either a pre-close or post-close approach. The company says existing suture devices were designed for smaller punctures and often require two or more devices per site. Ladera’s Large Bore Closure System remains limited by federal law to investigational use and is not available for sale in any country.
Comments (0)
No comments yet. Be the first!